{"id":3134,"date":"2024-06-10T11:22:27","date_gmt":"2024-06-10T15:22:27","guid":{"rendered":"https:\/\/cytel.agencyukdev.com\/perspectives\/bayesian-strategies-in-rare-diseases\/"},"modified":"2024-08-21T11:08:46","modified_gmt":"2024-08-21T15:08:46","slug":"bayesian-strategies-in-rare-diseases","status":"publish","type":"perspectives","link":"https:\/\/cytel.agencyukdev.com\/fr\/perspectives\/bayesian-strategies-in-rare-diseases\/","title":{"rendered":"Bayesian Strategies in Rare Diseases"},"content":{"rendered":"

When it comes to rare diseases, a handful of major challenges to drug development arise. Bayesians strategies have become a viable option, however, in overcoming some of the major obstacles faced by clinical trial sponsors in these areas.<\/p>\n

Due to the nature of the ailments in question (in the United States, a disease is considered “rare” if it affects fewer than 200,000 people; the European Union defines it as fewer than 5 in 10,000), a primary challenge for clinical trial sponsors is the small populations from which clinical trial participants can be recruited, which may be exacerbated by a reluctance of some to enroll in the control arm of the trial. A second challenge is limited knowledge of the disease’s natural history and the difficulty of defining appropriate endpoints that are feasibly measured during a clinical trial. Lastly, a third major challenge is access to accurate information on trial characteristics and patient outcomes that can be used to estimate a trial’s success rate.<\/p>\n

Bayesian strategies can help tackle these challenges, but as we saw in a previous article<\/a>, a major barrier to adopting these approaches is an unfamiliarity with Bayesian statistics among researchers in drug development and thus a reliance on standard designs that are not optimized to obtain data from small numbers of patients.<\/p>\n

To overcome this knowledge gap, Cytel’s Ursula Garczarek, Natalia Muehlemann, and Pranav Yajnik, along with their co-authors, in their recently published article in Therapeutic Innovation & Regulatory Science<\/em>, discuss how Bayesian approaches can be applied to drug development in rare diseases, including:<\/p>\n